




Searching News Database: kallikrein
HSMN NewsFeed - 3 Apr 2017
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
BioCryst Announces Mundipharma Receives Approval for Mundesine(R) in Japan
HSMN NewsFeed - 29 Nov 2016
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
HSMN NewsFeed - 12 Oct 2016
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
Global Blood Therapeutics Announces Appointment of Tricia Suvari as Chief Legal Officer
HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
HSMN NewsFeed - 30 Nov 2012
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
HSMN NewsFeed - 10 Feb 2009
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
Dyax and Fovea Sign Development and Commercialization Agreement for DX-88 in Ophthalmic Indications
HSMN NewsFeed - 4 Feb 2009
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
FDA Advisory Committee Favors Approval of DX-88 for Acute Attacks of Hereditary Angioedema
HSMN NewsFeed - 14 May 2007
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
Dyax Corp. Treats First Patient in Phase 2 Trial for On-Pump Cardiothoracic Surgery
HSMN NewsFeed - 17 Apr 2007
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
Dyax Initiates Confirmatory Phase 3 (EDEMA4) Trial for DX-88 for the Treatment of Hereditary Angioedema
HSMN NewsFeed - 12 Apr 2007
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3(R))
Additional items found! 10

Members Archive contains
10 additional stories matching:
kallikrein
(Password required)
kallikrein
(Password required)